Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

被引:0
作者
Morisco, Filomena [1 ,2 ,3 ]
Federico, Alessandro [4 ]
Marignani, Massimo [5 ,6 ]
Lombardo, Flavia L. [7 ]
Cossiga, Valentina [1 ,2 ]
Ranieri, Luisa [1 ,2 ]
Romeo, Mario [4 ]
Cipullo, Marina [4 ]
Begini, Paola [5 ]
Zannella, Alessandra [5 ]
Stroffolini, Tommaso [8 ]
机构
[1] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy
[2] AOU Federico II, Dept Program Dis Liver & Biliary Syst, I-80131 Naples, Italy
[3] Univ Naples Federico II, UNESCO Chair Environm Resources & Sustainable Dev, Dept Sci & Technol, I-80123 Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Hepatogastroenterol Unit, I-80138 Naples, Italy
[5] S Andrea Univ Hosp, Dept Digest & Liver Dis, I-00189 Rome, Italy
[6] Regina Apostolorum Hosp, Dept Gastroenterol & Hepatol, I-00041 Rome, Italy
[7] Italian Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, I-00161 Rome, Italy
[8] Policlin Umberto 1, Dept Trop & Infect Dis, I-00161 Rome, Italy
来源
VIRUSES-BASEL | 2024年 / 16卷 / 09期
关键词
direct-acting antiviral; SVR; LSM; HCC; HCV; CHRONIC HEPATITIS-C; ANTIVIRAL THERAPY; CIRRHOSIS; RISK;
D O I
10.3390/v16091439
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The prediction of liver-related events (LRE) after sustained virological response (SVR) in HCV-advanced chronic liver disease (ACLD) patients is crucial. We aimed to evaluate incidence and risk factors of LRE in HCV-cirrhotic patients after SVR and to assess dynamic changes of liver stiffness in participants without LRE at the end of follow-up. We enrolled 575 consecutive patients with HCV-ACLD treated with DAAs and followed up for 5 years after SVR12. Overall, 98 (17%) patients developed any type of event, and HCC was the most frequent LRE. The incidence rate was 1.6 per 100 person-years (p/y) for both HCC and hepatic decompensation. Baseline LSM >= 20 kPa was the only independent predictor of hepatic decompensation, while LSM >= 20 kPa and male sex were independent predictors of HCC development. Among the 341 participants without LRE and with paired LSM, any LSM reduction was observed in 314 (92.1%), and half of them showed a decrease of LSM >= 20%. Among patients without LRE, 27.3% of participants without >= 20% LSM decrease at 2 years achieved the 5-year goal; in contrast, 31.6% of participants with >= 20% LSM decrease at 2 years lost it at 5 years. These findings provide evidence that baseline LSM is a tool to stratify patients at risk of developing LRE; the dynamic changes of LSM value suggest the need for monitoring this parameter over time.
引用
收藏
页数:11
相关论文
共 29 条
  • [1] aifa, US
  • [2] BEDOSSA P, 1994, HEPATOLOGY, V20, P15
  • [3] Quality criteria for the measurement of liver stiffness
    Boursier, Jerome
    Decraecker, Marie
    Bourliere, Marc
    Bureau, Christophe
    Ganne-Carrie, Nathalie
    de Ledinghen, Victor
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (01)
  • [4] Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
    Calvaruso, Vincenza
    Cabibbo, Giuseppe
    Cacciola, Irene
    Petta, Salvatore
    Madonia, Salvatore
    Bellia, Alessandro
    Tine, Fabio
    Distefano, Marco
    Licata, Anna
    Giannitrapani, Lydia
    Prestileo, Tullio
    Mazzola, Giovanni
    Di Rosolini, Maria Antonietta
    Larocca, Licia
    Bertino, Gaetano
    Digiacomo, Antonio
    Benanti, Francesco
    Guarneri, Luigi
    Averna, Alfonso
    Iacobello, Carmelo
    Magro, Antonio
    Scalisi, Ignazio
    Cartabellotta, Fabio
    Savalli, Francesca
    Barbara, Marco
    Davi, Antonio
    Russello, Maurizio
    Scifo, Gaetano
    Squadrito, Giovanni
    Camma, Calogero
    Raimondo, Giovanni
    Craxi, Antonio
    Di Marco, Vito
    [J]. GASTROENTEROLOGY, 2018, 155 (02) : 411 - +
  • [5] Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
    Carrat, Fabrice
    Fontaine, Helene
    Dorival, Celine
    Simony, Melanie
    Diallo, Alpha
    Hezode, Christophe
    De Ledinghen, Victor
    Larrey, Dominique
    Haour, Georges
    Bronowicki, Jean-Pierre
    Zoulim, Fabien
    Asselah, Tarik
    Marcellin, Patrick
    Thabut, Dominique
    Leroy, Vincent
    Tran, Albert
    Habersetzer, Francois
    Samuel, Didier
    Guyader, Dominique
    Chazouilleres, Olivier
    Mathurin, Philippe
    Metivier, Sophie
    Alric, Laurent
    Riachi, Ghassan
    Gournay, Jerome
    Abergel, Armand
    Cales, Paul
    Ganne, Nathalie
    Loustaud-Ratti, Veronique
    D'Alteroche, Louis
    Causse, Xavier
    Geist, Claire
    Minello, Anne
    Rosa, Isabelle
    Gelu-Simeon, Moana
    Portal, Isabelle
    Raffi, Francois
    Bourliere, Marc
    Pol, Stanislas
    Bonnet, Delphine
    Payssan-Sicart, Virginie
    Pomes, Chloe
    Bailly, Francois
    Beaudoin, Marjolaine
    Giboz, Dominique
    Hartig-Lavie, Kerstin
    Maynard, Marianne
    Billaud, Eric
    Boutoille, David
    Cavellec, Morane
    [J]. LANCET, 2019, 393 (10179) : 1453 - 1464
  • [6] Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
    D'Ambrosio, Roberta
    Degasperi, Elisabetta
    Anolli, Maria Paola
    Fanetti, Ilaria
    Borghi, Marta
    Soffredini, Roberta
    Iavarone, Massimo
    Tosetti, Giulia
    Perbellini, Riccardo
    Sangiovanni, Angelo
    Sypsa, Vana
    Lampertico, Pietro
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 302 - 310
  • [7] Baveno VII - Renewing consensus in portal hypertension
    de Franchis, Roberto
    Bosch, Jaime
    Garcia-Tsao, Guadalupe
    Reiberger, Thomas
    Ripoll, Cristina
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 959 - 974
  • [8] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [9] Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients
    Fernandez-Alvarez, Paula
    Guerra-Veloz, Maria Fernanda
    Vilches-Arenas, Angel
    Cordero-Ruiz, Patricia
    Bellido-Munoz, Francisco
    Caunedo-Alvarez, Angel
    Carmona-Soria, Isabel
    [J]. VIRUSES-BASEL, 2023, 15 (06):
  • [10] Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis
    Foster, Graham R.
    Irving, William L.
    Cheung, Michelle C. M.
    Walker, Alex J.
    Hudson, Benjamin E.
    Verma, Suman
    McLauchlan, John
    Mutimer, David J.
    Brown, Ashley
    Gelson, William T. H.
    MacDonald, Douglas C.
    Agarwal, Kosh
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 (06) : 1224 - 1231